Review of tenofovir-emtricitabine

Highly active antiretroviral therapy has significantly reduced HIV-related morbidity and mortality. Increasingly, fixed-dose antiretroviral combinations with equal or greater potency than traditional antiretrovirals, along with fewer side effects, reduced toxicity, and simplified dosing convenience are being utilized. Tenofovir-emtricitabine (TDF-FTC) represents one of the more recent fixed-dose combinations. In combination with either a ritonavir-boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor, TDF-FTC is a preferred choice in recent treatment guidelines on the basis of demonstrated potency in randomized clinical trials, one-pill-a-day dosing convenience, and relatively low toxicity. In addition, the drug is active against hepatitis B virus. Caution must be exercised in patients with renal insufficiency, or when the drug is used with certain other drugs. This manuscript reviews the use of TDF-FTC in the treatment of HIV.

• Publication year

  2007

• Venue

  Therapeutics and Clinical Risk Management

• Publication date

  2007-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 18516268PMCID 2387297
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Emtricitabine

  2012cited by this paper
• The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV‐infected Patients

  2008cited by this paper
• Renal safety of tenofovir disoproxil fumarate.

  2007cited by this paper
• 8th International Congress on Drug Therapy in HIV Infection

  2007cited by this paper
• CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

  2007cited by this paper
• Prevalence of Antiretroviral Drug Resistance and Resistance-Associated Mutations in Antiretroviral Therapy-Naïve HIV-Infected Individuals from 40 United States Cities

  2007cited by this paper
• The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected Patients

  2007cited by this paper
• Renal Transport of Adefovir, Cidofovir, and Tenofovir by SLC22A Family Members (hOAT1, hOAT3, and hOCT2)

  2007cited by this paper
• Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate

  2007cited by this paper
• Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.

  2007cited by this paper
• Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection

  2007cited by this paper
• Chronic renal failure among HIV-1-infected patients

  2007cited by this paper
• No change in calculated creatinine clearance after tenofovir initiation among Thai patients.

  2007cited by this paper
• Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

  2006cited by this paper
• Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

  2006influential reference
• In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents

  2006cited by this paper
• Tenofovir disoproxil fumarate–emtricitabine coformulation for once-daily dual NRTI backbone

  2006cited by this paper
• Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel

  2006cited by this paper
• Treatment algorithm for chronic hepatitis B in HIV-infected patients.

  2006cited by this paper
• Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127

  2006cited by this paper
• Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

  2006cited by this paper
• Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis

  2006cited by this paper
• Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003

  2005cited by this paper
• Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients

  2005cited by this paper
• Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.

  2005cited by this paper
• Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir

  2005cited by this paper
• Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine

  2005cited by this paper
• Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.

  2005cited by this paper
• Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.

  2005cited by this paper
• Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

  2004cited by this paper
• Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.

  2004cited by this paper
• Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.

  2004cited by this paper
• A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV

  2004cited by this paper
• Tenofovir‐Related Nephrotoxicity: Case Report and Review of the Literature

  2004cited by this paper
• Tenofovir-related nephrotoxicity in HIV-infected patients.

  2004cited by this paper
• Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome.

  2003cited by this paper
• An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

  2003cited by this paper
• Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine

  2003cited by this paper
• Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection

  2003cited by this paper
• Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.

  2003cited by this paper
• Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001

  2003cited by this paper
• Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals

  2003cited by this paper
• Safety and Efficacy of Once-Daily Didanosine, Tenofovir and Nevirapine as a Simplification Antiretroviral Approach

  2003cited by this paper
• Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.

  2003cited by this paper
• Antiretroviral drug toxicity -- a challenge for the hepatologist?

  2002cited by this paper
• Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

  2002cited by this paper
• [Chronic hepatitis B].

  2001cited by this paper
• Chronic hepatitis B

  2001cited by this paper
• Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.

  2000cited by this paper
• Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.

  1999cited by this paper
• Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

  1998cited by this paper
• Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.

  1997cited by this paper
• Medical Management of HIV Infection

  1996cited by this paper
• [Chronic hepatitis].

  1995cited by this paper
• Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

  1992cited by this paper

• Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication

  2024cites this paper
• Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation

  2024cites this paper
• Oral PrEP Consultations Among Adolescent Girls and Young Women in Kisumu County, Kenya: Insights from the DREAMS Program

  2022cites this paper
• Multi-target direct-acting SARS-CoV-2 antivirals against the nucleotide-binding pockets of virus-specific proteins

  2022cites this paper
• Oral antiviral treatments for COVID-19: opportunities and challenges

  2022cites this paper
• Natural products and synthetic analogues against HIV: A perspective to develop new potential anti-HIV drugs.

  2022cites this paper
• Undisclosed exposure to antiretrovirals prior to treatment initiation: An exploratory analysis

  2021cites this paper
• Coadministration of ARV (Atripla) and Topiramate disrupts quail cardiac neural crest cell migration

  2021cites this paper
• HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases

  2021cites this paper
• Simultaneous Determination of Tenofovir Disoproxil Fumarate and Emtricitabine by UV Vierordt’s and UFLC Methods

  2021cites this paper
• Structural dynamics and susceptibility of anti-HIV drugs against HBV reverse transcriptase

  2020cites this paper
• Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection

  2020cites this paper
• Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID‐19

  2020cites this paper
• HIV-related Cardiovascular Diseases: the Search for a Unifying Hypothesis.

  2020cites this paper
• Synthesis of a long acting nanoformulated emtricitabine ProTide.

  2019cites this paper
• Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.

  2019cites this paper
• Chronic Nucleoside Reverse Transcriptase Inhibitors Disrupt Mitochondrial Homeostasis and Promote Premature Endothelial Senescence.

  2019cites this paper
• Development of a comprehensive 3D structural database of human pan-proteomic interaction with the most valuable sold drugs

  2019cites this paper
• Infection par le VIH-1 groupe O : étude des caractéristiques épidémiologiques et de la réponse immuno-virologique aux antirétroviraux

  2018cites this paper
• Drug Profile of Emtricitabine and Tenofovir AF

  2018cites this paper
• Combination ART-Induced Oxidative/Nitrosative Stress, Neurogenic Inflammation and Cardiac Dysfunction in HIV-1 Transgenic (Tg) Rats: Protection by Mg

  2018cites this paper
• Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection

  2018cites this paper
• Resistance Mechanisms to HIV-1 Nucleoside Reverse Transcriptase Inhibitors

  2017cites this paper
• Bioanalysis and pharmacokinetics-pharmacodynamics modeling of the endogenous 2'deoxynucleoside triphosphate pool in individuals receiving tenofovir/emtricitabine

  2017influential citation
• Simultaneous Method for Determination of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir and Cobicistat in Tablets by HPLC

  2016cites this paper
• A Rapid Stability Indicating RP-HPLC Method and the Degradation Kinetics Data for the Simultaneous Estimation of Tenofovir Disoproxil Fumarate and Emtricitabine

  2015cites this paper
• PrEP: A case study

  2015cites this paper
• Emtricitabine prodrugs with improved anti-HIV activity and cellular uptake.

  2013cites this paper
• Method Development and Validation for Simultaneous Estimation of Emtricitabine and Tenofovir Disoproxil Fumarate in Pure and Tablet Dosage Form by using RP-HPLC

  2013cites this paper
• Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine.

  2012cites this paper
• Quantitative Analysis of Tenofovir by Titrimetric, Extractive Ion-pair Spectophotometric and Charge- Transfer Complexation Methods

  2011cites this paper
• Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes

  2009cites this paper
• Design and Evaluation of Nucleoside Derivatives for Targeted Drug Delivery and Therapeutic Applications

  2008cites this paper